Ovarian cancer is a lethal disease with a high mortality rate, accounting for about 3% of all cancers among women, and is the fifth leading cause of cancer death in women. Current front-line treatments use platinum-based anticancer agents, such as cisplatin and carboplatin. However, Ovarian cancer inevitably acquires resistance to these drugs when cancer cells become insensitive to the effects of platinum-based chemotherapy, leading to treatment failure and disease progression. Thus, one major challenge in managing ovarian cancer is the development of new strategies for early identification and drug therapies to overcome platinum resistance.
Several studies have investigated the relationship between platinum resistance and ovarian cancer. Among these, genetic mutations, changes in protein expression, and circulating tumor DNA were associated with platinum resistance in ovarian cancer cells. Clinical trials have also demonstrated the potential utility of platinum resistance as a predictive biomarker for ovarian cancer. Therefore, fully understanding the mechanisms underlying platinum resistance in ovarian cancer is crucial to develop new diagnostic tools and more effective drugs to predict and overcome platinum resistance in ovarian cancer.
In this Research Topic, we aim to promote discussion on the emerging molecular targets and clinical strategies being explored for treatment planning and improving responses to ovarian cancer platinum-based chemotherapy. We welcome submissions that cover, but are not limited to:
- Dysregulation of transporters associated with platinum-based drugs
- Platinum resistance via the formation of drug conjugates
- Interaction between and expression of molecules that promotes platinum resistance by inducing DNA damage
- Changes in gene expression and the molecular pathways modulating cancer cell apoptosis and proliferation under platinum-based chemotherapy
- New molecular and fluorescent markers for diagnosing and treating platinum-resistant ovarian cancer
- microRNAs and other noncoding RNAs in ovarian cancer platinum resistance
- Liquid biopsy for platinum-resistant ovarian cancer management
- Strategies for monitoring drug responses and disease recurrences in ovarian cancer patients treated with platinum-based drugs
- Tumor stem cell plasticity in ovarian cancer platinum resistance
-Strategies to combine available and future drugs to overcome platinum resistance
- Analysis of histopathologic and molecular changes in platinum-resistant tumors
- impact of surgery on avoiding platinum-resistant tumor cells clones
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Ovarian cancer is a lethal disease with a high mortality rate, accounting for about 3% of all cancers among women, and is the fifth leading cause of cancer death in women. Current front-line treatments use platinum-based anticancer agents, such as cisplatin and carboplatin. However, Ovarian cancer inevitably acquires resistance to these drugs when cancer cells become insensitive to the effects of platinum-based chemotherapy, leading to treatment failure and disease progression. Thus, one major challenge in managing ovarian cancer is the development of new strategies for early identification and drug therapies to overcome platinum resistance.
Several studies have investigated the relationship between platinum resistance and ovarian cancer. Among these, genetic mutations, changes in protein expression, and circulating tumor DNA were associated with platinum resistance in ovarian cancer cells. Clinical trials have also demonstrated the potential utility of platinum resistance as a predictive biomarker for ovarian cancer. Therefore, fully understanding the mechanisms underlying platinum resistance in ovarian cancer is crucial to develop new diagnostic tools and more effective drugs to predict and overcome platinum resistance in ovarian cancer.
In this Research Topic, we aim to promote discussion on the emerging molecular targets and clinical strategies being explored for treatment planning and improving responses to ovarian cancer platinum-based chemotherapy. We welcome submissions that cover, but are not limited to:
- Dysregulation of transporters associated with platinum-based drugs
- Platinum resistance via the formation of drug conjugates
- Interaction between and expression of molecules that promotes platinum resistance by inducing DNA damage
- Changes in gene expression and the molecular pathways modulating cancer cell apoptosis and proliferation under platinum-based chemotherapy
- New molecular and fluorescent markers for diagnosing and treating platinum-resistant ovarian cancer
- microRNAs and other noncoding RNAs in ovarian cancer platinum resistance
- Liquid biopsy for platinum-resistant ovarian cancer management
- Strategies for monitoring drug responses and disease recurrences in ovarian cancer patients treated with platinum-based drugs
- Tumor stem cell plasticity in ovarian cancer platinum resistance
-Strategies to combine available and future drugs to overcome platinum resistance
- Analysis of histopathologic and molecular changes in platinum-resistant tumors
- impact of surgery on avoiding platinum-resistant tumor cells clones
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
